Skip to main content

Friday, November 11, 2022 | 11am EST (NA)

WEBINAR: NGS Applications for Antiviral Drug Development & FDA Guidance for Data Submission

Accurate detection and monitoring of minority variants that confer drug and antiviral resistance is critical to therapeutic and vaccine trials. Specifically, it aids in controlling the emergence of novel variants that can potentially lead to outbreaks of disease and breakthrough infections.

In this webinar Dr. Kirthi Kutambuka, Senior Research Scientist, explores the following case study:

Viracor Biopharma Services has developed and validated a next-generation sequencing (NGS) assay to determine the genetic variability in the F gene of respiratory syncytial virus (RSV) isolated from human nasal swab (NS) specimens. The NGS method has several advantages over standard Sanger sequencing related to higher sensitivity, quantifiable, cost effective and automatable data analysis steps. 

Register now for this webinar to learn more about the applications of this NGS assay in antiviral drug development

Merck Recognizes Eurofins Viracor BioPharma with "Top Performer" Award

In recognition for their dedication and successful execution of the PCR assay validation supporting a recent Merck clinical development project.

Building Bridges

Eurofins Viracor BioPharma

With Cutting edge technology and a specialized team of R&D scientists, Eurofins Viracor BioPharma has been supporting clients through multiple phases of drug development for over thirty-five years.

We’re experts in developing, customizing, and validating assays for complex clinical research testing. Our broad laboratory capabilities offer services covering infectious disease, immune response, allergy hypersensitivity, oncology, and more.

 

 

 

Expertise

We’re driven to partner with you to solve difficult scientific problems, complementing your strategies with expertise in complex method development on multiple technology platforms, validation, and transfer. Our Research & Development team serves as an extension of your laboratory, with unique skills in technology platform selection and protocol design.

Agility

Eurofins Viracor BioPharma leverages over 16 different technology platforms and accepts a broad range of specimen types, widening our capabilities and enabling us to customize testing to your exact needs for your clinical trial combined with the scalability to manage trials of any size. We are also a CAP accredited/CLIA certified laboratory and we adhere to GCLP guidelines.

Speed

Our high-throughput laboratory can support your clinical trials with the capacity to process large sample volumes quickly, support studies with short set up timelines and provide rapid turnaround times. Our project managers and scientists act as part of your team – going above and beyond to get you the results you need when you need them. Accelerating your vaccine, compound, immune therapy or biological from bench to market.

Eurofins Viracor Biopharma is a trusted provider of drug development solutions to pharmaceutical and contract research organizations. We offer complex/esoteric testing and assay development, to help advance your Phase 1-4 clinical trials through trusted partnership, scientific excellence and exceptional service.

For more than 35 years, Viracor has been dedicated to helping clients by providing high quality, accurate results to evaluate the effects of drug candidates across all major therapeutic categories. We offer broad experience in molecular infectious disease testing, vaccine safety and efficacy assessment, immunogenicity, cell-based assays, allergy/ hypersensitivity, and biomarker analysis. Our validated test list includes more than 3000 assays, with new custom assays developed on a continual basis, in response to client needs.

Back to top